Ariel Hammerman1, Joseph Azuri2,3, Enis Aboalhasan4, Ronen Arbel5. 1. Department of Pharmaceutical Technology Assessment, Clalit Health Services Headquarters, Tel-Aviv, Israel. 2. Diabetes Clinic, Central District, Maccabi Healthcare Services, Tel Aviv, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel. 5. Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel. ronen.arbel@gmail.com.
Abstract
BACKGROUND: Comorbid heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (DM) is associated with a very high risk of HF events. Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), and dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, improve HF outcomes in these patients, but their comparative value for money in this patient population has not yet been determined. OBJECTIVE: We aimed to compare the cost needed to treat (CNT) to avoid an HF event with each drug. METHODS: CNT was estimated by multiplying the annualized number needed to treat (NNT) to prevent one HF event by the annual cost of each therapy. HF events were defined as the first event of hospitalization for HF or cardiovascular mortality. Drug efficacy data were extracted from published secondary analyses of patients with DM in the DAPA-HF and PARADIGM-HF trials. Drug costs were estimated as 75% of the 2021 US National Average Drug Acquisition Cost listing. Sensitivity analysis was performed on parameters that may have affected the CNT. RESULTS: The annualized NNT was 24 (95% confidence interval [CI] 16-54) for dapagliflozin and 57 (95% CI 31-433) for the ARNI. At an annual cost of $US4523 and 5099, respectively, the CNT was $US108,563 (95% CI 72,375-244,267) for dapagliflozin and $US290,671 (95% CI 158,084-2,208,079) for the ARNI. CONCLUSIONS: Dapagliflozin seems to offer greater value for money than the ARNI for patients with HFrEF and DM. Our results provide support for contemporary guidelines advocating the use of dapagliflozin in these patients.
BACKGROUND: Comorbid heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (DM) is associated with a very high risk of HF events. Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), and dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, improve HF outcomes in these patients, but their comparative value for money in this patient population has not yet been determined. OBJECTIVE: We aimed to compare the cost needed to treat (CNT) to avoid an HF event with each drug. METHODS: CNT was estimated by multiplying the annualized number needed to treat (NNT) to prevent one HF event by the annual cost of each therapy. HF events were defined as the first event of hospitalization for HF or cardiovascular mortality. Drug efficacy data were extracted from published secondary analyses of patients with DM in the DAPA-HF and PARADIGM-HF trials. Drug costs were estimated as 75% of the 2021 US National Average Drug Acquisition Cost listing. Sensitivity analysis was performed on parameters that may have affected the CNT. RESULTS: The annualized NNT was 24 (95% confidence interval [CI] 16-54) for dapagliflozin and 57 (95% CI 31-433) for the ARNI. At an annual cost of $US4523 and 5099, respectively, the CNT was $US108,563 (95% CI 72,375-244,267) for dapagliflozin and $US290,671 (95% CI 158,084-2,208,079) for the ARNI. CONCLUSIONS: Dapagliflozin seems to offer greater value for money than the ARNI for patients with HFrEF and DM. Our results provide support for contemporary guidelines advocating the use of dapagliflozin in these patients.
Authors: Wilfried Mullens; Angelo Auricchio; Pieter Martens; Klaus Witte; Martin R Cowie; Victoria Delgado; Kenneth Dickstein; Cecilia Linde; Kevin Vernooy; Francisco Leyva; Johann Bauersachs; Carsten W Israel; Lars H Lund; Erwan Donal; Giuseppe Boriani; Tiny Jaarsma; Antonio Berruezo; Vassil Traykov; Zaheer Yousef; Zbigniew Kalarus; Jens Cosedis Nielsen; Jan Steffel; Panos Vardas; Andrew Coats; Petar Seferovic; Thor Edvardsen; Hein Heidbuchel; Frank Ruschitzka; Christophe Leclercq Journal: Eur J Heart Fail Date: 2020-12 Impact factor: 15.534
Authors: Ibrahim Sultan; Jennifer Paech; Karthik Amudhala Hemanthakumar; Christer Betsholtz; Bin Zhou; Riikka Kivelä; Markus Räsänen; Wei Yu; Liqun He; Juan Tang; Ying Sun; Ruslan Hlushchuk; Xiuzheng Huan; Emma Armstrong; Oleksiy-Zakhar Khoma; Eero Mervaala; Valentin Djonov; Kari Alitalo Journal: Circulation Date: 2020-11-18 Impact factor: 29.690
Authors: Mark C Petrie; Subodh Verma; Kieran F Docherty; Silvio E Inzucchi; Inder Anand; Jan Belohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andre Dukát; Junbo Ge; Jonathan Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Pham Nguyen Vinh; Morten Schou; Sergey Tereshchenko; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Per Johanson; Peter J Greasley; David Boulton; Olof Bengtsson; Pardeep S Jhund; John J V McMurray Journal: JAMA Date: 2020-04-14 Impact factor: 56.272
Authors: Phil McEwan; Oliver Darlington; John J V McMurray; Pardeep S Jhund; Kieran F Docherty; Michael Böhm; Mark C Petrie; Klas Bergenheim; Lei Qin Journal: Eur J Heart Fail Date: 2020-09-15 Impact factor: 15.534